Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
STAMFORD, Conn., March 02, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, March 9, 2017, at 4:30 p.m. ET to report fourth quarter and full year 2016 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 70053458. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
